Trial Profile
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Sunitinib
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms OCLURANDOM
- 13 Sep 2022 Status changed to active, no longer recruiting.
- 13 Sep 2022 Primary endpoint (To determine the 12 months PFS) has been met, according to Results presented at the 47th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress